Concepedia

David Erlinge

DE

Statistics

Publications

5

Citations

149

H-Index

5

Active since

1999

Affiliations

Lund University(Current)

Uppsala University

Linköping University

Daiichi-Sankyo (South Korea)

Sahlgrenska University Hospital

David Erlinge is an author at Lund University specializing in pharmacology, pharmacogenomics in cardiology, and cyp2c19 pharmacogenetics.

Publications per year

1999–2025

5

Publications

5

Increase in cardiac P2X1- and P2Y2-receptor mRNA levels in congestive heart failure

Mingyan Hou, Malin Malmsjö, Sebastian Möller et al. · Life Sciences · 1999 · 62 citations

, , +8

The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Thomas O. Bergmeijer, Udaya S. Tantry, Jurriën M. ten Berg et al. · Thrombosis and Haemostasis · 2014 · 32 citations · Full text

, , +17

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

Stefan James, Suman Duvvuru, Joseph A. Jakubowski et al. · Thrombosis and Haemostasis · 2014 · 21 citations

, , +17

Coronary Computed Tomography Angiography in Prediction of First Coronary Events

Göran Bergström, Gunnar Engström, Elias Björnson et al. · JAMA · 2025 · 19 citations · Full text

, , +17

Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy

Margrét Leósdóttir, Lars Dahlbom, Maria Bäck et al. · American Heart Journal · 2025 · 15 citations · Full text

, , +16

1–5 of 5